Biomimetic nanodelivery systems, methods of making and using the same
By constructing a biomimetic nanodelivery system with a "core-shell-membrane" structure, the targeting and hepatotoxicity issues of MCC950 in the treatment of myocardial ischemia-reperfusion injury were solved, achieving efficient drug delivery and cardioprotective effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-01
- Publication Date
- 2026-07-17
AI Technical Summary
In the existing technology, MCC950, as an NLRP3 inflammasome inhibitor, has problems such as poor targeting, easy clearance and hepatotoxicity in the treatment of myocardial ischemia-reperfusion injury, making it difficult to achieve an effective therapeutic concentration in the heart.
A biomimetic nanodelivery system is designed, using mesoporous polydopamine as the core, with cationic liposomes and macrophage membranes sequentially coated on the outer layer to form a "core-shell-membrane" structure. It utilizes ROS/pH dual-responsive release and inflammatory chemotaxis targeting capabilities to achieve efficient drug delivery and inhibition of pyroptosis.
This approach achieves highly efficient targeted drug delivery to the site of myocardial ischemia-reperfusion injury, reduces liver distribution, lowers hepatotoxicity, significantly inhibits cardiomyocyte pyroptosis, alleviates myocardial damage, and improves treatment efficiency.
Smart Images
Figure CN122398749A_ABST